{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T05:48:48Z","timestamp":1791611328565,"version":"4.3.4"},"reference-count":8,"publisher":"Japanese Urological Association","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Jpn. j. urol"],"published-print":{"date-parts":[[2025,10,20]]},"DOI":"10.5980\/jpnjurol.116.126","type":"journal-article","created":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T22:13:14Z","timestamp":1791497594000},"page":"126-129","source":"Crossref","is-referenced-by-count":0,"title":["OLAPARIB TREATMENT IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER WITH BRCA2 MUTATION AND HIGH TUMOR MUTATIONAL BURDEN: A CASE REPORT","BRCA2\u907a\u4f1d\u5b50\u5909\u7570\u304a\u3088\u3073TMB-high\u3068\u3082\u306b\u967d\u6027\u306e\u53bb\u52e2\u62b5\u6297\u6027\u524d\u7acb\u817a\u764c\u306b\u5bfe\u3057\u3066Olaparib\u6cbb\u7642\u3092\u884c\u3063\u305f1\u4f8b"],"prefix":"10.5980","volume":"116","author":[{"given":"Takehiro","family":"Nakashima","sequence":"first","affiliation":[{"name":"Department of Urology, Yokohama Sakae Kyosai Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika","family":"Soga","sequence":"additional","affiliation":[{"name":"Department of Urology, Yokohama Sakae Kyosai Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshitaka","family":"Miyai","sequence":"additional","affiliation":[{"name":"Department of Urology, Yokohama Sakae Kyosai Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masazumi","family":"Nagashima","sequence":"additional","affiliation":[{"name":"Department of Urology, Yokohama Sakae Kyosai Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4001","reference":[{"key":"1","unstructured":"1) \u65e5\u672c\u6ccc\u5c3f\u5668\u79d1\u5b66\u4f1a, \u65e5\u672c\u75c5\u7406\u5b66\u4f1a, \u65e5\u672c\u533b\u5b66\u653e\u5c04\u7dda\u5b66\u4f1a\u7de8: \u524d\u7acb\u817a\u764c\u53d6\u6271\u3044\u898f\u7d04, \u7b2c5\u7248, p 107-108, \u30e1\u30c7\u30a3\u30ab\u30eb\u30ec\u30d3\u30e5\u30fc\u793e, \u5927\u962a, 2022."},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Bono JS de, Fizazi K, Saad F, Shore N, Sandhu SK, Mehra N, Kolinsky M, Roubaud G, \u00d6zg\u00fcroglu M, Matsubara N, Gedye C, Choi YD, Padua C, Goessl C, Kohlmann A, Corcoran C, Adelman CA, Allen A, Burgents J and Hussain M: 847PD - Central, prospective detection of homologous recombination repair gene mutations (HRRm) in tumour tissue from >4000 men with metastatic castration-resistant prostate cancer (mCRPC) screened for the PROfound study. Ann Oncol., 13, v328-329, 2019.","DOI":"10.1093\/annonc\/mdz248.004"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Castro E, Laorden NR, Pozo AD, Lozano R, Medina A, Puente J, Piulats JM, Lorente D, Saez MI, Barrera RM, Billalabeitia EG, Cend\u00f3n Y, Carbonero IG, Borrega P, Jos\u00e9 Mendez Vidal M, Montesa A, Nombela P, Parra EF, Del Alba AG, Villa-Guzm\u00e1n JC, Ib\u00e1\u00f1ez K, Vida AR, Pardo LM, Valderrama BP, Vallesp\u00edn E, Gallardo E, Vazquez S, Pritchard CC, Lapunzina P and Olmos D: PROREPAIR-B: A Prospective Cohort Study of the Impact of Germline DNA Repair Mutations on the Outcomes of Patients With Metastatic Castration-Resistant Prostate Cancer. J Clin Oncol., 37, 490-503, 2019.","DOI":"10.1200\/JCO.18.00358"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Abida W, Cheng ML, Armenia J, Middha S, Autio KA, Vargas HA, Rathkopf D, Morris MJ, Danila DC, Slovin SF, Carbone E, Barnett ES, Hullings M, Hechtman JF, Zehir A, Shia J, Jonsson P, Stadler ZK, Srinivasan P, Laudone VP, Reuter V, Wolchok JD, Socci ND, Taylor BS, Berger MF, Kantoff PW, Sawyers CL, Schultz N, Solit DB, Gopalan A and Scher HI: Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade. JAMA Oncol., 5, 471-478, 2019.","DOI":"10.1001\/jamaoncol.2018.5801"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Lenis AT, Ravichandran V, Brown S, Alam SM, Katims A, Truong H, Reisz PA, Vasselman S, Nweji B, Autio KA, Morris MJ, Slovin SF, Rathkopf D, Danila D, Woo S, Vargas HA, Laudone VP, Ehdaie B, Reuter V, Arcila M, Berger MF, Viale A, Scher HI, Schultz N, Gopalan A, Donoghue MT A, Ostrovnaya I, Stopsack KH, Solit DB and Abida W: Microsatellite Instability, Tumor Mutational Burden, and Response to Immune Checkpoint Blockade in Patients with Prostate Cancer. Clin Cancer Res., 30, 3894-3903, 2024.","DOI":"10.1158\/1078-0432.CCR-23-3403"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Bono J de, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S, Chi KN, Sartor O, Agarwal N, Olmos D, Vuillemin AT, Twardowski P, Mehra N, Goessl C, Kang J, Burgents J, Wu W, Kohlmann A, Adelman CA and Hussain M: Olaparib for Metastatic Castration-Resistant Prostate Cancer. N Engl J Med., 382, 2091-2102, 2020.","DOI":"10.1056\/NEJMoa1911440"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Rebuzzi SE, Rescigno P, Catalano F, Mollica V, Vogl UM, Marandino L, Massari F, Mestre RP, Zanardi E, Signori A, Buti S, Bauckneht M, Gillessen S, Banna GL and Fornarini G: Immune Checkpoint Inhibitors in Advanced Prostate Cancer: Current Data and Future Perspectives. Cancers (Basel), 28, 1245, 2022.","DOI":"10.3390\/cancers14051245"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Inoue T, Sekito S, Kageyama T, Sugino Y and Sasaki T: Roles of the PARP Inhibitor in BRCA1 and BRCA2 Pathogenic Mutated Metastatic Prostate Cancer: Direct Functions and Modification of the Tumor Microenvironment. Cancers (Basel), 15, 2662, 2023.","DOI":"10.3390\/cancers15092662"}],"container-title":["The Japanese Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jpnjurol\/116\/4\/116_126\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T04:55:19Z","timestamp":1791608119000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jpnjurol\/116\/4\/116_126\/_article\/-char\/ja\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,20]]},"references-count":8,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.5980\/jpnjurol.116.126","relation":{},"ISSN":["0021-5287","1884-7110"],"issn-type":[{"value":"0021-5287","type":"print"},{"value":"1884-7110","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,20]]}}}